EP 1068193 A1 20010117 - BENZYLPIPERAZINYL- AND BENZYLPIPERIDINYL ETHANONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D 4? RECEPTOR ANTAGONISTS
Title (en)
BENZYLPIPERAZINYL- AND BENZYLPIPERIDINYL ETHANONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D 4? RECEPTOR ANTAGONISTS
Title (de)
BENZYLPIPERAZINYL- UND BENZYLPIPERIDINYL ETHANON DERIVATE, DEREN HERSTELLUNG UNDDEREN VERWENDUNG ALS DOPAMIN D4 REZEPTOR ANTAGONISTEN
Title (fr)
DERIVES DE BENZYLPIPERAZINYL ET PIPERIDINYL ETHANONE, PREPARATION, ET UTILISATION COMME ANTAGONISTES DES RECEPTEURS D 4? DE LA DOPAMINE
Publication
Application
Priority
- US 9904309 W 19990226
- US 3098798 A 19980226
Abstract (en)
[origin: WO9943670A1] Disclosed are compounds of formula (I) or pharmaceutically acceptable addition salts thereof wherein: Y represents oxygen or sulfur; Z is nitrogen or CH; R1, R2 and R3 represents hydrogen, halogen, hydroxy, alkoxy, alkyl, trifluoromethyl or trifluoromethoxy; R4 and R4' represent hydrogen, alkyl or form a ring with the atom to which they are attached; R5 represents hydrogen, alkyl, alkoxy, or alkylthio, and R6 represents hydrogen or alkyl; or R5 and R6 form a ring together with the atoms to which they are attached; and R7, R8, R9, R10 and R11 represent hydrogen or alkyl, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents. Also encompassed within the scope of the invention are intermediates of formulae (VII-a) and (VII-b) wherein X represents oxygen, or sulfur, or CH2, m is zero or an integer of from 1-4, and L is a leaving group.
IPC 1-7
C07D 401/06; A61K 31/445; C07D 295/14; A61K 31/495; C07D 209/08; C07D 215/08; C07D 265/36; A61K 31/535; C07D 279/16; A61K 31/54; C07D 209/54
IPC 8 full level
A61K 31/4427 (2006.01); A61K 31/445 (2006.01); A61K 31/4523 (2006.01); A61K 31/454 (2006.01); A61K 31/4709 (2006.01); A61K 31/495 (2006.01); A61K 31/496 (2006.01); A61K 31/5375 (2006.01); A61K 31/538 (2006.01); A61K 31/5415 (2006.01); A61K 31/55 (2006.01); C07D 295/14 (2006.01); A61P 25/00 (2006.01); A61P 25/16 (2006.01); A61P 25/18 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); A61P 25/30 (2006.01); A61P 43/00 (2006.01); C07D 209/08 (2006.01); C07D 209/54 (2006.01); C07D 209/96 (2006.01); C07D 211/34 (2006.01); C07D 215/08 (2006.01); C07D 221/20 (2006.01); C07D 223/16 (2006.01); C07D 225/06 (2006.01); C07D 265/36 (2006.01); C07D 267/22 (2006.01); C07D 279/16 (2006.01); C07D 295/15 (2006.01); C07D 401/06 (2006.01); C07D 413/06 (2006.01); C07D 417/06 (2006.01)
CPC (source: EP KR)
A61P 25/00 (2018.01 - EP); A61P 25/16 (2018.01 - EP); A61P 25/18 (2018.01 - EP); A61P 25/22 (2018.01 - EP); A61P 25/24 (2018.01 - EP); A61P 25/28 (2018.01 - EP); A61P 25/30 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07D 209/08 (2013.01 - EP KR); C07D 209/54 (2013.01 - EP KR); C07D 215/08 (2013.01 - EP KR); C07D 265/36 (2013.01 - EP KR); C07D 279/16 (2013.01 - EP KR); C07D 295/15 (2013.01 - EP KR); C07D 401/06 (2013.01 - EP KR)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9943670 A1 19990902; AU 2881499 A 19990915; CA 2321830 A1 19990902; CN 1293669 A 20010502; EP 1068193 A1 20010117; HU P0100926 A2 20010928; HU P0100926 A3 20030328; IL 137930 A0 20011031; JP 2002504549 A 20020212; KR 20010041341 A 20010515; NO 20004271 D0 20000825; NO 20004271 L 20001025; PL 342597 A1 20010618
DOCDB simple family (application)
US 9904309 W 19990226; AU 2881499 A 19990226; CA 2321830 A 19990226; CN 99804026 A 19990226; EP 99909657 A 19990226; HU P0100926 A 19990226; IL 13793099 A 19990226; JP 2000533426 A 19990226; KR 20007009454 A 20000825; NO 20004271 A 20000825; PL 34259799 A 19990226